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SUMMARY
DNA methylation plays crucial roles in chromatin structure and gene expression. Aberrant DNA 
methylation patterns, including global hypomethylation and regional hypermethylation, are 
associated with cancer and implicated in oncogenic events. How DNA methylation is regulated in 
developmental and cellular processes and dysregulated in cancer is poorly understood. Here, we 
show that PRMT6, a protein arginine methyltransferase responsible for asymmetric dimethylation 
of histone H3 arginine 2 (H3R2me2a), negatively regulates DNA methylation and that PRMT6 
upregulation contributes to global DNA hypomethylation in cancer. Mechanistically, PRMT6 
overexpression impairs chromatin association of UHRF1, an accessory factor of DNMT1, 
resulting in passive DNA demethylation. The effect is likely due to elevated H3R2me2a, which 
inhibits the interaction between UHRF1 and histone H3. Our work identifies a mechanistic link 
between protein arginine methylation and DNA methylation, which is disrupted in cancer.
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Veland et al. find that PRMT6, an arginine methyltransferase responsible for histone H3 arginine 2 
(H3R2) methylation, negatively regulates maintenance DNA methylation by impairing UHRF1 
recruitment to chromatin. The authors also find that PRMT6 upregulation contributes to global 
DNA hypomethylation in cancer cells.
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INTRODUCTION
In mammals, DNA methylation (5-methylcytosine, 5mC) is mostly restricted to CpG 
dinucleotides and plays crucial roles in many biological processes. Aberrant DNA 
methylation is associated with cancer. Specifically, cancer cells generally exhibit global 
hypomethylation and loci-specific hypermethylation, which are implicated in genomic 
instability and tumor suppressor silencing, respectively (Baylin and Jones, 2016). However, 
the mechanisms underlying these alterations remain largely unclear.
DNA methylation patterns are established by the de novo DNA methyltransferases 
DNMT3A and DNMT3B and maintained primarily by the maintenance enzyme DNMT1. 
DNMT1 recruitment to hemi-methylated CpG sites during DNA replication depends on 
UHRF1, a multi-domain protein (Bostick et al., 2007, Sharif et al., 2007). The SRA (SET- 
and RING-associated) domain of UHRF1 preferentially binds hemi-methylated DNA and 
plays an important role in loading DNMT1 onto newly synthesized DNA (Bostick et al., 
2007, Sharif et al., 2007, Liu et al., 2013). The RING domain-mediated ubiquitination of 
lysine residues in the N-terminal tail of histone H3 promotes DNMT1 association with H3 
(Nishiyama et al., 2013, Qin et al., 2015, Harrison et al., 2016). Moreover, the TTD (tandem 
Tudor domain) and PHD (plant homeodomain) cooperatively interact with the N-terminal 
tail of H3 by recognizing a specific histone modification signature. Specifically, the TTD 
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exhibits affinity for di- and tri-methylated lysine 9 (H3K9me2/me3) (Rothbart et al., 2012, 
Rothbart et al., 2013, Liu et al., 2013), whereas PHD-mediated binding to H3 is disrupted by 
arginine 2 (H3R2) methylation (Rajakumara et al., 2011, Hu et al., 2011, Wang et al., 2011, 
Lallous et al., 2011). Recent studies show that the SRA domain interaction with DNA 
stimulates TTD-PHD-mediated H3 binding and that hemi-methylated DNA recognition 
allosterically activates RING domain-mediated H3 ubiquitination (Harrison et al., 2016, 
Fang et al., 2016). These data suggest that UHRF1 targets DNMT1 to newly replicated DNA 
through complex interactions with chromatin.
The observation that the UHRF1 PHD specifically binds unmodified, but not H3R2-
methylated, N-terminal tail of H3 suggests that DNA methylation may be modulated by 
H3R2 methylation. Arginine methylation is carried out by the PRMT family, consisting of 
nine members (Bedford and Richard, 2005). PRMT6 is the primary enzyme responsible for 
asymmetric dimethylation of H3R2 (H3R2me2a) (Guccione et al., 2007, Hyllus et al., 2007, 
Iberg et al., 2008). Notably, PRMT6 is frequently overexpressed in cancer cells and 
implicated in tumorigenic functions (Yang and Bedford, 2013). In this study, we show that 
PRMT6 negatively regulates DNA methylation by impairing UHRF1 association with 
chromatin and that its overexpression contributes to global DNA hypomethylation in cancer.
RESULTS
PRMT6 overexpression induces global DNA hypomethylation in mESCs
Given that H3R2 methylation disrupts UHRF1-H3 interaction (Rajakumara et al., 2011, Hu 
et al., 2011, Wang et al., 2011, Lallous et al., 2011), we hypothesized that PRMT6, the 
primary enzyme responsible for H3R2me2a, regulates DNA methylation. To test the idea, 
we generated mouse embryonic stem cell (mESC) clones overexpressing human PRMT6 by 
stable transfection of a bicistronic vector expressing Myc-tagged PRMT6 and the 
blasticidin-resistant gene (Figure 1A). mESCs offer an ideal experimental system for 
studying DNA methylation regulators, as their survival and proliferation are not affected by 
DNA methylation loss (Tsumura et al., 2006).
As expected, PRMT6 overexpression resulted in elevated H3R2me2a levels, which 
correlated with reduced H3K4me3 levels, consistent with previous reports that H3R2 
methylation antagonizes H3K4me3 (Guccione et al., 2007, Kirmizis et al., 2007, Hyllus et 
al., 2007). As controls, H3K9me3 and total H3 showed no alterations (Figure 1B). Notably, 
PRMT6 overexpression also led to increases in arginine methylation of non-histone proteins 
(Figure S1A). The stable clones maintained the mESC state, as judged by colony 
morphology, growth rates, and expression of the pluripotency factors Nanog, Sox2 and Oct4 
(Figures S1B–S1D).
To assess the impact of PRMT6 overexpression on DNA methylation, we first analyzed the 
minor satellite repeats (MSR) and intracisternal A-particle (IAP) retrotransposons. Southern 
blot analysis of genomic DNA digested with the methylation-sensitive restriction enzyme 
HpaII revealed that cells expressing Myc-PRMT6 exhibited marked DNA hypomethylation 
compared to cells transfected with the empty vector (mock) (Figures 1C and 1D). We then 
confirmed global DNA hypomethylation in PRMT6-overexpressing mESCs with dot blot 
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and immunofluorescence (IF) analyses using a 5mC antibody (Figures 1E–1G). The effect 
of PRMT6 on DNA methylation depends on its catalytic activity, as an inactive PRMT6 
mutant (E155Q) failed to induce DNA hypomethylation in mESCs (Figures S2A–S2C). 
Together, these results demonstrate that PRMT6 and its methyltransferase activity negatively 
regulate global DNA methylation.
PRMT6 overexpression impairs Uhrf1 association with chromatin
To determine the mechanism by which PRMT6 induces DNA hypomethylation, we first 
examined the expression of Dnmts, as well as key regulators of DNA methylation, including 
Uhrf1 (murine Uhrf1 is also known as Np95), PCNA and Usp7. None of the proteins 
showed changes in PRMT6-overexpressing cells (Figure 2A). We then tested the hypothesis 
that increased H3R2me2a negatively affects Uhrf1 binding to chromatin. Nuclear 
fractionation experiments revealed that Uhrf1 chromatin association reduced dramatically in 
PRMT6-overexpressing mESCs compared to mock mESCs (~10% vs. ~60%) (Figures 2B 
and 2C). Chromatin immunoprecipitation (ChIP) analysis confirmed that increased 
H3R2me2a levels correlated with decreased Uhrf1 enrichment at MSR and IAP regions 
(Figures 2D and 2E). These results support our hypothesis that higher H3R2me2a levels 
induced by PRMT6 overexpression impair Uhrf1 association with chromatin, resulting in a 
failure in maintaining DNA methylation.
PRMT6 upregulation correlates with DNA hypomethylation in human cancers
Global DNA hypomethylation is a hallmark of cancer cells (Baylin and Jones, 2016), but the 
underlying mechanisms are poorly understood. Given that overexpression of PRMT6 is 
reported in multiple types of cancer (Yang and Bedford, 2013), we postulated that PRMT6 
upregulation might contribute to global DNA hypomethylation.
We first assessed the correlation between PRMT6 expression and DNA methylation in a 
panel of human cell lines. Compared to non-tumorigenic breast cell lines 76NF2V and MCF 
10F, most cancer cell lines examined exhibited upregulation of PRMT6, although the levels 
varied greatly (Figure 3A). The 5mC content in the cancer cell lines was measured by liquid 
chromatography and tandem mass spectrometry (LC-MS/MS) (Table S1). Based on the 
relative levels of PRMT6 (Figure 3A), we divided the cancer cell lines into two groups: the 
PRMT6-high group had significantly lower levels of 5mC than the PRMT6-low group 
(Figure 3B).
We next asked whether PRMT6 upregulation correlates with DNA hypomethylation in 
primary tumor samples by employing The Cancer Genome Atlas (TCGA) database. Data 
downloaded from the cBioPortal for Cancer Genomics showed wide variations in PRMT6 
expression in all cancer types (Figure S3). We selected three common cancer types, i.e. 
breast cancer, lung cancer and colorectal cancer, because a large amount of DNA 
methylation data is available in the TCGA database. When all samples of each cancer type 
were included in the analyses, no clear correlation was observed between PRMT6 
expression and DNA methylation levels, which is not surprising because both PRMT6 and 
DNA methylation levels are highly variable. However, comparisons of the samples with the 
highest 20% and lowest 20% of PRMT6 expression revealed a significant inverse correlation 
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between PRMT6 expression and DNA methylation in lung cancer and colorectal cancer, but 
not in breast cancer (Figure 3C). Based on our hypothesis, DNA methylation may not be 
affected by PRMT6 if UHRF1 expression is low. Therefore, we first divided the samples 
into UHRF1-high (upper 70%) and UHRF1-low (lower 30%) groups and then compared 
DNA methylation levels in samples with high (top 20%) and low (bottom 20%) PRMT6 
expression. Consistent with our hypothesis, we observed a significant inverse correlation 
between PRMT6 expression and DNA methylation in the UHRF1-high groups of all the 
three cancer types (Figure 3D upper panel) and no correlations in the UHRF1-low groups 
(Figure 3D lower panel). Together, these data suggest that PRMT6 upregulation contributes 
to global DNA hypomethylation in cancer.
PRMT6 depletion or inhibition restores global DNA methylation in MCF7 cells
To validate the significance of PRMT6 upregulation in DNA hypomethylation, we assessed 
the impact of PRMT6 knockdown (KD) and inhibition in MCF7 cells, a breast cancer cell 
line with high PRMT6 expression (Figure 3A). Stable expression of PRMT6 shRNAs, which 
efficiently depleted PRMT6 (Figure 4A), or treatment with MS023, a PRMT inhibitor that is 
potent for PRMT6 (Eram et al., 2016), resulted in substantial decreases in H3R2me2a, but 
no changes in DNMT1 and UHRF1 levels (Figures 4A and 4C). Consistent with previous 
reports (Neault et al., 2012, Stein et al., 2012, Phalke et al., 2012, Kleinschmidt et al., 2012, 
Eram et al., 2016), PRMT6 KD or MS023 treatment resulted in defects in MCF7 
proliferation (Figures S4A–S4D). Dot blot analysis showed that PRMT6 depletion or 
inhibition led to increases in global DNA methylation (Figures 4B and 4D). We verified the 
results by bisulfite sequencing analysis of a region in the 45S ribosomal DNA (rDNA) 
promoter, which is partially methylated in MCF7 cells (Karahan et al., 2015). Indeed, 
PRMT6 KD or MS023-treated cells had markedly higher levels of DNA methylation (~90%) 
than control cells (~60%) (Figure 4E). Both de novo and maintenance methylation probably 
contributed to the restoration of DNA methylation levels.
In agreement with our hypothesis, UHRF1 chromatin association was substantially enhanced 
in cells treated with MS023 (Figures 4F and 4G). In addition, we analyzed UHRF1 
occupancy at the promoter regions of three PRMT6 target genes, HOXA2, CDKN1A and 
GREB1C (Hyllus et al., 2007, Kleinschmidt et al., 2012, Phalke et al., 2012, Mann et al., 
2014). ChIP and methylated-DNA immunoprecipitation (MeDIP) analyses confirmed that 
H3R2me2a reduction induced by MS023 correlated with increases in UHRF1 enrichment 
and DNA methylation levels at these loci (Figures 4H–4J). Collectively, these results suggest 
that, in MCF7 cells, PRMT6 upregulation plays a critical role in inducing global DNA 
hypomethylation by impairing UHRF1 chromatin binding.
DISCUSSION
Various epigenetic mechanisms act cooperatively in regulating chromatin structure and gene 
activity. While it has been well established that DNA methylation and several histone 
modifications, notably lysine methylation, are functionally linked (Rothbart et al., 2012, Du 
et al., 2015), much less clear is the crosstalk between DNA methylation and arginine 
methylation. In this study, we demonstrate that PRMT6 is a negative regulator of DNA 
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methylation. We show that overexpression of PRMT6 in mESCs compromises Uhrf1 
association with chromatin. Consistent with previous evidence that H3R2 methylation 
inhibits Uhrf1-H3 interaction (Rajakumara et al., 2011, Hu et al., 2011, Wang et al., 2011, 
Lallous et al., 2011, Rothbart et al., 2013), our results indicate that the catalytic activity of 
PRMT6 is required for its effect on DNA methylation. Thus, we propose that PRMT6, by 
generating H3R2me2a, impairs recruitment of the Dnmt1-Uhrf1 complex to newly 
replicated DNA, resulting in passive DNA demethylation. However, we cannot rule out the 
possibility that PRMT6-mediated methylation of other arginine residues on histone or non-
histone proteins also contributes to DNA methylation changes.
While the relevance of PRMT6 in regulating DNA methylation in normal developmental and 
cellular processes remains to be determined, we provide evidence that PRMT6 
overexpression contributes to global DNA hypomethylation in cancer cells. We show that 
PRMT6 expression levels inversely correlate with DNA methylation levels in both cancer 
cell lines and primary cancer tissues. Moreover, PRMT6 depletion or inhibition leads to 
restoration of DNA methylation levels in MCF7 cells, suggesting a causal link between 
PRMT6 overexpression and DNA hypomethylation. While most PRMT6 high-expressing 
cell lines have relatively low levels of DNA methylation, some cell lines that are severely 
hypomethylated (e.g., MDA-MB 231, SKBR3) show no obvious PRMT6 upregulation 
(Figure 3A and Table S1), suggesting that multiple mechanisms are involved in DNA 
hypomethylation in cancer. Some of the mechanisms likely affect the functionality of the 
DNMT1-UHRF1 complex. UHRF1 could positively or negatively impact DNA methylation. 
On one hand, UHRF1 is essential for DNMT1 recruitment to newly replicated DNA to 
maintain DNA methylation (Bostick et al., 2007, Sharif et al., 2007). On the other hand, 
UHRF1, an E3 ubiquitin ligase, can ubiquitinate UHRF1 itself, DNMT1 and DNMT3A, 
leading to their degradation (Jenkins et al., 2005, Du et al., 2010, Qin et al., 2011, Jia et al., 
2016). UHRF1 is highly expressed in many cancers (Yang and Bedford, 2013), which likely 
contributes to DNA methylation changes. Indeed, overexpression of human UHRF1 in 
zebrafish hepatocytes leads to Dnmt1 mislocalization and degradation, DNA 
hypomethylation, and hepatocellular carcinoma (Mudbhary et al., 2014).
PRMT6 is overexpressed in multiple types of cancer. In breast cancer, PRMT6 levels 
positively correlate with tumor stages, suggesting that PRMT6 may contribute to tumor 
progression (Phalke et al., 2012). Nevertheless, we observed that the benign breast cancer 
cell line MCF7 has higher levels of PRMT6 than the aggressive cell line MDA-MB 231 
(Figure 3A), indicating that the relationship between PRMT6 expression and cancer 
invasiveness is complex. The differences could be attributed to the different cancer subtypes 
that the cell lines represent. How PRMT6 overexpression contributes to tumorigenesis 
remains to be determined. PRMT6 generally functions as a transcriptional repressor, 
although it has also been shown to act as a co-activator of nuclear receptors such as estrogen 
receptor (Yang and Bedford, 2013). In this study, we demonstrate that PRMT6 
overexpression contributes to DNA hypomethylation, which could lead to genomic 
instability and expression of cancer-promoting genes. Importantly, the effect of PRMT6 on 
DNA methylation is reversible, as PRMT6 depletion or inhibition restores DNA methylation 
levels in MCF7 cells. This raises the possibility of targeting PRMT6 for cancer therapy. 
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However, it remains to be determined to what extent PRMT6-dependent DNA 
hypomethylation contributes to tumorigenesis and maintenance of the tumor phenotype.
EXPERIMENTAL PROCEDURES
Cell culture and manipulations
mESCs culture and generation of stable clones were described previously (Dan et al., 2017). 
Human cancer cell lines were cultured according to instructions of American Type Culture 
Collection. For PRMT6 KD, MCF7 cells transfected with shRNA plasmids were selected 
and maintained in medium containing 1 μg/ml of puromycin. To inhibit PRMT6 activity, 
cells were treated with 10 μM of MS023 (Eram et al., 2016).
Nuclear fractionation
Nuclear fractionation in mESCs was carried out as described previously (Mendez and 
Stillman, 2000) with the following modification: buffer B was replaced by buffer N [15 mM 
Tris-HCl (pH 7.5), 200 mM NaCl, 60 mM KCl, 5 mM MgCl2, 1 mM CaCl2, 0.3% NP-40, 
and 1X protease inhibitor cocktail (Thermo Scientific)]. For experiments in MCF7 cells, 
NaCl in buffer N was adjusted to 100 mM.
DNA methylation analyses
Southern blot, dot blot and IF analyses of DNA methylation were performed as described 
previously (Dan et al., 2017). For bisulfite sequencing analysis, bisulfite conversion was 
performed using EZ DNA Methylation Kit (Zymo), PCR products cloned using NEB PCR 
cloning kit, and individual clones sequenced. Quantification of 5mC content was done by 
LC-MS/MS.
ChIP and MeDIP
ChIP assays were performed as described previously (Dan et al., 2017). For MeDIP, RNA-
free genomic DNA was sonicated and incubated with 2 μg of 5mC antibody (Millipore) in 
MeDIP buffer [10 mM Na-Phosphate (pH 7.0), 140 mM NaCl, and 0.05% Triton X-100] for 
3 hours at 4°C. Dynabeads M-280 sheep anti-mouse IgG (Thermo Scientific) were used to 
precipitate DNA complexes.
Bioinformatics and statistical analysis
PRMT6 expression data and DNA methylation data for breast cancer, lung adenocarcinoma 
and colorectal adenocarcinoma samples in TCGA database were analyzed. The mean DNA 
methylation levels of samples with the highest (top 20%) and lowest (bottom 20%) PRMT6 
expression were compared either without taking UHRF1 expression into consideration or by 
first dividing the samples into UHRF1-high (upper 70%) and UHRF1-low (lower 30%) 
groups. Wilcoxon rank sum non-parametric test with two-tailed P value was used to 
determine the significance of differences in Figures 3B–3D. Paired t test with two-tailed P 
value was used for Figure 1F.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• PRMT6 overexpression induces histone H3R2me2a and DNA 
hypomethylation in mESCs
• Uhrf1 association with chromatin is impaired in mESCs overexpressing 
PRMT6
• PRMT6 upregulation correlates with DNA hypomethylation in cancer cells
• PRMT6 depletion or inhibition restores DNA methylation in MCF7 cells
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Figure 1. Overexpression of PRMT6 in mESCs induces global DNA hypomethylation
(A) Diagram of Myc-PRMT6 plasmid.
(B) Western blots showing the levels of Myc-PRMT6 and histone marks in stable mESC 
clones. Mock, mESCs transfected with empty vector. Uhrf−/−, Uhrf1 knockout mESCs.
(C and D) Southern blots showing DNA methylation at MSR (C) and IAP (D) after 
digestion of genomic DNA with the methylation-sensitive restriction enzyme HpaII.
(E) Dot blot analysis of genomic DNA with 5mC antibody (left). The same membrane was 
stained with SYTOX Green to verify equal DNA loading (right).
(F) Quantification of data in (E) by densitometry using Image J. Shown are relative 5mC 
levels (mean + SD from three independent experiments). Paired t test was used to determine 
statistical significance. **P < 0.01.
(G) IF analysis with 5mC antibody. Scale bars, 15 μm.
See also Figure S1 and Figure S2.
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Figure 2. Uhrf1 chromatin association is impaired in mESCs overexpressing PRMT6
(A) Western blots showing the levels of DNA methylation enzymes and regulators. Note that 
mESCs express two major Dnmt3a isoforms (Dnmt3a and Dnmt3a2) and that the Dnmt3a 
antibody cross-reacts with Dnmt3b.
(B) Nuclear fractionation assay showing Uhrf1 chromatin association. PCNA and HP1α 
were used as controls for soluble and chromatin-associated proteins, respectively.
(C) Quantification of data in (B) by densitometry using Image J. Shown are percentages of 
soluble and chromatin-associated Uhrf1 in each sample (mean + SD from three independent 
experiments).
(D and E) ChIP assays showing relative enrichment of H3R2me2a (D) and Uhrf1 (E) at 
MSR and IAP regions (mean + SD from three independent experiments).
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Figure 3. PRMT6 expression inversely correlates with DNA methylation in human cancer cells
(A) Western blots showing PRMT6 levels in human cancer cell lines. BR NT, breast non-
tumorigenic; BRCA, breast cancer; PCA, prostate cancer; COAD, colorectal 
adenocarcinoma; LUAD, lung adenocarcinoma; NB, neuroblastoma; OS, osteosarcoma.
(B) Comparison between PRMT6-high and PRMT6-low cell lines for 5mC levels 
(determined by LC-MS/MS, see Table S1).
(C and D) Correlation of PRMT6 expression and DNA methylation data from the TCGA 
database. The mean DNA methylation levels between cancer samples with the highest (top 
20%) and lowest (bottom 20%) PRMT6 expression in each cancer type were compared, 
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either without considering UHRF1 expression (C) or by dividing all samples into UHRF1-
high (upper 70%) and UHRF1-low (lower 30%) groups before analysis (D). Note that the 
30% cutoff for UHRF1 expression was based on merged datasets of the three cancer types 
and, therefore, the sample numbers of UHRF1-high and UHRF1-low groups in each cancer 
type do not make up precisely 70% and 30%, respectively.
Wilcoxon rank sum non-parametric test with two-tailed P value was used to determine the 
significance of differences in (B–D). *P < 0.05; **P < 0.01; ns, not significant.
See also Table S1 and Figure S3.
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Figure 4. PRMT6 depletion or inhibition restores DNA methylation in MCF7 cells
(A and C) Western blot analysis of MCF7 cells stably transfected with PRMT6 shRNAs (A) 
or treated with MS023 (C).
(B and D) 5mC dot blot analysis of samples in (A) and (C), respectively. DNA loading was 
verified by SYTOX Green staining.
(E) Bisulfite sequencing analysis of a 45S rDNA promoter region containing 27 CpG sites. 
Open circles, unmethylated CpGs; Filled circles, methylated CpGs.
(F) Nuclear fractionation of MCF7 cells treated with MS023 for UHRF1 chromatin 
association. PCNA and HP1α were used as controls for soluble and chromatin-associated 
proteins, respectively.
(G) Quantification of data in (F) by densitometry using Image J. Shown are percentages of 
soluble and chromatin-associated UHRF1 in each sample (mean + SD from three 
independent experiments).
(H–J) ChIP or MeDIP assays showing relative enrichment of H3R2me2a (H) and UHRF1 
(I) or relative DNA methylation levels (J) at HOXA2, CDKN1A and GREB1C promoter 
regions (mean + SD from three independent experiments).
MS023 treatment was performed at 10 μM for 4 days for all experiments.
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See also Figure S4.
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